Table 2.

BI 894999 effect on the proliferation of ex vivo-treated AML and MM primary patient samples

Indication	Patient	BI 894999 EC50 (nM)	Karyotype ISCN 2005	Cytogenetic risk group classification
AML	Patient 1	4	46,XX	Intermediate
AML	Patient 2	<1	46,XY	Intermediate
AML	Patient 3	5	46,XY	Intermediate
AML	Patient 4	1083	46,XY add(3)(q27),−7,del (10)(q22),+15 47,XY,−7,+8,+15 46,XY,der(15)t(1;15)(q10;p10) 46,XY	High
AML	Patient 5	89	47,XY,−7,+8,+15	High
AML	Patient 6	2	46,XY,der(15)t(1;15)(q10;p10)	Intermediate
AML	Patient 7	12	46,XY	Intermediate
AML	Patient 8	2	45,XY,−7/45,XY, der (3)del (3) (p11p21),−7	High
AML	Patient 9	5	46,XY	Intermediate
AML	Patient 10	<1	46,XX,add(9)(q34),t(11;19)(q23;p13.3/ 46,XX	High
AML	Patient 11	18	46,XY,t(9;11)(p11;q23)	High
AML	Patient 12	4	46,XY	Intermediate
AML	Patient 13	<1	46,XX	Intermediate
AML	Patient 14	<1	NA	NA
AML	Patient 15	1	46,XY, inv(9)(p11q13) c	Intermediate
AML	Patient 16	<1	NA	NA
AML	Patient 17	<1	46,XX,t(9;11)(p22;q23)	High
AML	Patient 18	<1	46,XX	Intermediate
AML	Patient 19	<1	46,XY	Intermediate
AML	Patient 20	<1	46,XY	Intermediate
MM	Patient 1	52	NA	NA
MM	Patient 2	15	NA	NA
MM	Patient 3	7	NA	NA
MM	Patient 4	>2000	NA	NA
MM	Patient 5	500	NA	NA
MM	Patient 6	421	NA	NA
MM	Patient 7	54	NA	NA
MM	Patient 8	3	NA	NA
MM	Patient 9	21	NA	NA
MM	Patient 10	1	NA	NA
MM	Patient 11	57	NA	NA
MM	Patient 12	1361	NA	NA
MM	Patient 13	2	NA	NA
MM	Patient 14	275	NA	NA
MM	Patient 15	352	NA	NA

NA - not available